Table 3 Venous thromboembolism treatment depending on CKD stage and professional group
| Â | Haematology | Nephrology doctors | Renal pharmacists |
|---|---|---|---|
CKD stage 4 | |||
  DOACs n/N (%) | 9/13 (69%) | 29/35 (83) | 32/38 (84%) |
  LMWH n/N (%) | 5/13 (38%) | 7/35 (20) | 19/38 (50%) |
  VKA n/N (%) | 5/13 (38%) | 19/35 (54) | 27/38 (71%) |
CKD stage 5 | |||
  DOACs n/N (%) | 1/13 (8%) | 15/35 (43%) | 6/37 (16%) |
  LMWH n/N (%) | 4/13 (31%) | 8/35 (23%) | 30/37 (81%) |
  VKA n/N (%) | 10/13 (77%) | 26/35 (74%) | 30/37 (81%) |
Dialysis | |||
  DOACs n/N (%) | 1/13 (8%) | 14/35 (40%) | 6/37 (16%) |
  LMWH n/N (%) | 5/13 (38%) | 9/35 (26%) | 29/37 (78%) |
  VKA n/N (%) | 9/13 (69%) | 25/35 (71%) | 32/37 (86%) |
Kidney transplant | |||
  DOACs n/N (%) | 7/12 (58%) | 29/35 (83%) | 31/37 (84%) |
  LMWH n/N (%) | 6/12 (50%) | 8/35 (23%) | 20/37 (54%) |
  VKA n/N (%) | 9/12 (75%) | 19/35 (54%) | 26/37 (70%) |